Clinical Trial Update: Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing standard-dose versus double-dose dolutegravir in people with HIV-associated tuberculosis has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: University of Cape Town | Conditions: HIV Infections, Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2023-09-18